Agendia BV Appoints New Chief Financial Officer
HUNTINGTON BEACH, California, and AMSTERDAM, January 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Kurt Schmidt, CPA, MBA, as the company's new Chief Financial Officer.
"Kurt is an exceptional addition to our team and an invaluable asset," said Bernhard Sixt, Ph.D., President and Chief Executive Officer. "With his extensive financial management experience in the high tech and healthcare industries, he will be instrumental in driving Agendia's next phase of growth."
Mr. Schmidt succeeds former Chief Financial Officer, John de Die, who has been an exemplary guide for Agendia during his tenure. Mr. Schmidt brings more than 25 years of financial, operational and entrepreneurial management experience, primarily in the high tech and healthcare industries in the U.S. and Europe. Most recently, he was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Prior to that, Mr. Schmidt served as Operations Director at B2eMarkets, a supply chain technology company, and Director of Finance & Operations at LA Gear Europe. Mr. Schmidt started his career at Cardinal Health, Inc. in corporate finance.
"I am delighted to join Agendia during this exciting time and help prepare the company for our next financing round. I look forward to our first investor meetings next week during the JP Morgan Healthcare Conference in San Francisco," commented Kurt Schmidt, Chief Financial Officer.
About Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.
CONTACT: MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191 Mobile,
vdelva@ricochetpr.com